BeOne

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

R&D

Interview at BIO 2025 with Jeffrey Meckler

Going wide on immune system activation, with Jeffrey Meckler

Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

News

AZ claims EU approval for new Calquence regimens in CLL

AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.

News

BeiGene abandons TIGIT antibody after lung cancer flop

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.

Sales & Marketing

12 Questions with Giancarlo Benelli

Giancarlo Benelli brings over two decades of experience in the pharmaceutical industry, rooted in his unique journey from surgery and military service.

Sales & Marketing

12 Questions with Pilar de la Rocha Mur

Pilar de la Rocha Mur is Head of Clinical Operations EMEA (Europe, Middle East, and Africa) at BeiGene.

NICE backs new drugs for Crohn's disease, lymphoma

Going wide on immune system activation, with Jeffrey Meckler

AZ claims EU approval for new Calquence regimens in CLL

BeiGene abandons TIGIT antibody after lung cancer flop

12 Questions with Giancarlo Benelli

12 Questions with Pilar de la Rocha Mur

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

BeOne

Editor's Picks